Evotec Bundle
Who owns Evotec and who controls its direction?
Evotec SE’s shareholder mix shifted sharply after the 2023–2024 cyberattack and trading halt, spotlighting institutional moves and voting dynamics. Founded in Hamburg in 1993, Evotec now focuses on integrated drug discovery with global sites and partnership-based revenue streams.
Major ownership is held by European and U.S. institutions with a large free float and no founding family control; recent volatility amplified stakes and governance scrutiny. See Evotec Porter's Five Forces Analysis for competitive context.
Who Founded Evotec?
Founders and Early Ownership of Evotec trace to a 1993 science-led founding team that combined Nobel-level research with entrepreneurial management to scale a discovery services platform.
Founding team
Evotec was co-founded in 1993 by Dr. Manfred Eigen, Dr. Karsten Henco, Dr. Ulrich Schwabe and Dr. Rainer Rudolph, with early management contributors such as Dr. Thomas Meier.
Scientific leadership
Dr. Manfred Eigen brought Nobel-level scientific credibility; other founders provided molecular biology, chemistry and protein engineering expertise that shaped initial IP and service offerings.
Early capital mix
Initial funding combined founder common equity, German venture and strategic backers, regional innovation grants and technology-transfer funds from Hamburg/Lower Saxony ecosystems.
Cap table dynamics
Founders and early employees collectively held the majority pre-IPO; exact percentage splits were not publicly itemized, with typical German biotech vesting (four-year vesting, one-year cliff) applied.
Institutional dilution
Late-1990s institutional venture rounds and strategic pharma collaborations often included equity kickers or warrants, diluting founders while aligning incentives to milestone progress.
Professionalisation
Scientific founders gradually moved to advisory roles; executive leadership and institutional investors assumed greater control as the company prepared for public markets and scale-up under later CEOs such as Dr. Werner Lanthaler.
Early ownership set Evotec on a path from founder-majority science venture to an institutional investor–driven public company, with founder stakes reduced by financing, collaboration-linked equity and partial liquidity events.
Key facts and implications
Founders, early investors and structural features that shaped Evotec ownership:
- Founders: Dr. Manfred Eigen, Dr. Karsten Henco, Dr. Ulrich Schwabe, Dr. Rainer Rudolph; early management: Dr. Thomas Meier.
- Pre-IPO majority: founders and early employees collectively held the majority; specific splits not publicly disclosed.
- Typical vesting: German biotech practice in the 1990s commonly used 4-year vesting with a 1-year cliff.
- Funding sources: regional innovation grants, technology-transfer funds, European venture capital and strategic pharma collaborations with equity kickers.
For more on strategic evolution and later investor composition see Growth Strategy of Evotec.
Evotec SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Evotec’s Ownership Changed Over Time?
Key events reshaping Evotec ownership include the 1999–2000 Neuer Markt IPO that dispersed founder/VC control, the 2008–2010 acquisition-driven pivot and equity issuances, index inclusion and rising institutional accumulation during 2016–2019, pandemic-era market cap expansion and convertible issuance in 2020–2022, and the 2023 cyber incident that prompted trading suspension and portfolio rebalancing.
| Period | Ownership Shift | Notable Stakeholders / Effects |
|---|---|---|
| 1999–2000 | IPO on Neuer Markt; founder/VC control → dispersed public float | Initial market cap peaked at several hundred million euros during dot‑com/biotech boom; early‑2000s valuation normalization |
| 2008–2010 | Strategic M&A and equity issuance | Acquisitions (including U.S. deal in 2008) modestly diluted holders; CEO Dr. Werner Lanthaler (2009) shifted governance toward partnership/milestone model |
| 2016–2019 | Index inclusion; institutional accumulation | Major long‑only funds and index trackers increased positions; free float > 85% |
| 2020–2022 | Pandemic tailwinds; convertible bonds | Market cap reached multi‑billion euros (peak 2021); convertible issue in 2021 added potential dilution; partnerships with large pharmas strengthened investor confidence |
| 2023–2024 | Cyber incident; trading suspension and volatility | Institutional rebalancing; top holders diversified below 10%; institutional ownership estimated ~60–75% |
Evotec SE retains one‑share‑one‑vote governance without dual‑class shares; management and employees hold a minority stake while institutional holders dominate liquidity and governance expectations.
Ownership snapshot and implications
Institutional accumulation over 2016–2024 drove a stable, high free float and shifted focus to recurring revenue, capital discipline and strengthened disclosure standards.
- Top global indexers and asset managers (BlackRock, Vanguard, DWS, Norges Bank, Amundi) consistently appear among largest holders in filings
- Major partnerships (Bayer, Bristol Myers Squibb, Novo Nordisk) reduced perceived development risk and attracted long‑only funds
- Convertible bonds and periodic equity issuance introduced potential dilution events investors monitor
- Cybersecurity and governance became priority shareholder concerns after April 2023 incident
Key factual pointers for investors: Evotec ownership structure is public, free float historically > 85%, institutional ownership commonly estimated between 60–75%, no controlling shareholder disclosed as of 2024–2025 filings, and shareholder registries and periodic disclosures list top holders typically in the 3–9% range when crossing German voting thresholds; see the company profile and this article on Marketing Strategy of Evotec for related context.
Evotec PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Evotec’s Board?
The current Supervisory Board of Evotec AG (2024–2025) is led by an independent chair and comprises industry, pharma R&D, healthcare services, finance and compliance experts; the company follows a German two-tier governance system with a separate Management Board handling operations. Voting at Evotec is one-share-one-vote with no public dual-class or special founder voting rights disclosed.
| Body | Role | Typical Expertise |
|---|---|---|
| Supervisory Board | Oversight, appoints Management Board | Pharma R&D, finance, compliance, strategic partnerships |
| Management Board | Executive management, operations | Drug discovery, biotech operations, commercial execution |
Board seats are not formally reserved for specific shareholders; institutional holders and large investors exert influence via AGM voting, engagement and say-on-pay, while the majority of Supervisory Board members are classified as independent under the German Corporate Governance Code. Shareholder scrutiny intensified after the 2023 cyber incident and R&D leadership transitions, but no proxy battles reaching a vote were widely reported through 2025.
Board composition and voting power
Evotec’s governance reflects one-share-one-vote equity ownership, independent supervisory oversight, and active institutional investor engagement.
- Voting: one-share-one-vote; no public dual-class or golden shares
- Supervisory Board: majority independent under German Corporate Governance Code
- Large institutional holders influence outcomes via AGM votes and engagement
- AGM resolutions follow AktG thresholds applicable to SEs; quorum and majority per law
As of 2025, public filings and institutional disclosures show that the largest Evotec shareholders are a mix of global asset managers and European institutional investors, with free float comprising the majority of listed shares; for detailed revenue and ownership context see Revenue Streams & Business Model of Evotec.
Evotec Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Evotec’s Ownership Landscape?
Evotec ownership has trended toward broader institutional dispersion since 2021, with free float remaining above 85% and no controlling shareholder emerging; recent financings, governance events and strategic focus have shifted investor mix toward Europe-domiciled asset managers and passive indexers.
| Year | Key ownership/financing event | Effect on shareholders |
|---|---|---|
| 2021–2022 | Convertible bond issuance (low single-digit coupon, mid/late-decade maturity) | Potential dilution; proceeds funded biologics and iPSC capacity expansion and partnering programs; boosted institutional interest |
| 2023 | Cybersecurity incident and trading halt (Apr–May 2023) | Share drawdown triggered active fund rebalancing; passive indexers largely maintained exposure; governance scrutiny increased |
| 2024 | Emphasis on milestone/royalty-backed programs; modest rise in Europe-based institutional concentration | No major buybacks; free float >85%; analysts flagged strategic partnerships or bolt-on M&A as likeliest moves |
| 2025 YTD | Diversified register; top holders typically sub-10%; insider stakes low single digits | Higher passive ownership, governance focus on cybersecurity; no public activist campaign or privatization signal |
Institutional ownership concentration rose modestly in 2024–2025, with top 10 holders often composed of European asset managers and global passive funds; insiders and executives hold low single-digit stakes, and management has reiterated capital allocation toward fee-for-service scale, milestone/royalty deals and net leverage reduction from prior convertibles.
Convertible impact
Proceeds from the 2021–2022 convertible bond supported biologics and iPSC platform expansion and partnering programs while creating dilution risk that investors monitor.
Governance and cybersecurity
The April–May 2023 trading halt heightened governance scrutiny and prompted active-holder rebalancing; passive indexers largely retained positions.
Ownership profile 2025
As of 2025 YTD, ownership remains diversified: free float >85%, top holders sub-10%, and insiders holding low single-digit percentages; no controlling shareholder is present.
Strategic outlook
Future ownership shifts are likeliest via strategic investors entering through partnerships or sector consolidation (CRO/CRDMO/discovery services) rather than a founder-led privatization.
For further context on market positioning and partner strategies see Target Market of Evotec
Evotec Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Evotec Company?
- What is Competitive Landscape of Evotec Company?
- What is Growth Strategy and Future Prospects of Evotec Company?
- How Does Evotec Company Work?
- What is Sales and Marketing Strategy of Evotec Company?
- What are Mission Vision & Core Values of Evotec Company?
- What is Customer Demographics and Target Market of Evotec Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.